Lewy Body Dementia Treatment Market

Lewy Body Dementia Treatment Market Outlook (2023 to 2033)

Worldwide demand for Lewy body dementia treatment accounts for a market value of US$ 4.7 billion in 2023. Across the study period (2023 to 2033), the global Lewy body dementia treatment market size is predicted to expand steadily at 6% CAGR and reach US$ 8.45 billion by the end of 2033.

The build-up of protein masses known as Lewy bodies in certain brain cells is the prime Lewy body dementia cause. It is most likely to affect people above 50 years of age and can also be synonymous with other neurodegenerative disorders. The rapidly expanding geriatric population around the world is necessitating the demand for advanced Lewy body dementia diagnosis and prognosis, which is slated to create new opportunities for companies operating in this space.

Increasing availability of Lewy body dementia support groups and Lewy body dementia treatment options are also slated to impact market development across the study period.

• Lewy body dementia life expectancy ranges between 2 to 20 years on average, while most people live for around 5 to 8 years after diagnosis.

Governments are launching initiatives to promote awareness regarding Lewy body dementia symptoms and improve Lewy body dementia care for all. Increasing public and private investments in Lewy body dementia research is also projected to increase the number of Lewy body dementia clinical trials over the next ten years.

• For instance, the U.S. has passed a law called the BOLD Infrastructure for Alzheimer’s Act, an initiative aimed at forming a public health model against Alzheimer’s disease and other dementias. The law was passed in December 2018 and sanctioned approx. US$ 100 million over a period of five years to enhance public education, launch dementia initiatives, and collect and distribute data related to cognitive decline.

Considering the high cost of certain Lewy body dementia treatment medications and Lewy body dementia treatment therapies, healthcare insurance providers, and governments are focusing on drafting new reimbursement policies that would improve Lewy body dementia treatment insurance coverage in the future. High costs of Lewy body dementia treatment and late diagnosis of the condition are anticipated to be the prime constraints limiting lewy body dementia treatment market growth scope through 2033.

Report Attributes	Details
Lewy Body Dementia Treatment Market Size (2023)	US$ 4.7 Billion
Projected Market Value (2033F)	US$ 8.45 Billion
Global Market Growth Rate (2023 to 2033)	6% CAGR
Leading Regional Market (2023)	North America
Key Companies Profiled	BioArctic AB; Eisai Co. Ltd.; Noven Pharmaceuticals Inc.; Eli Lilly and Company; Novartis AG; Pfizer Inc.; Mylan NV; Sumitomo Dainippon Pharma Co. Ltd.; Jazz Pharmaceuticals Inc.; Bayer AG; Allergan Plc.; Sanofi AG; Teva Pharmaceuticals; GlaxoSmithKline; Takeda Pharmaceutical Company Ltd.; Janssen Pharmaceuticals Inc.; Bausch Health Companies Inc.; Mallinckrodt Pharmaceuticals

How are Start-ups Trying to Maximize Their Business Scope in This Space?

“Capital Raise for Lewy Body Dementia Research Crucial for New Companies”

The need for a proper treatment for dementia has been around for years and with modern advancements in the healthcare industry, companies think can make dementia treatment a reality. Developing a treatment requires huge capital investment from the research to development and commercialization process and this is why incoming Lewy body dementia treatment providers are focusing on raising funds to finance their efforts in the future.

• In May 2023, Violet Therapeutics Inc., a pre-clinical stage company focusing on cellular connectome, announced that it had raised US$ 10.6 million in a seed financing round. Dementia Discovery Fund (DDF) led the round with the University of Tokyo Edge Capital Partners (UTEC) and participation from other investors.

Rising awareness regarding dementia and the immense scope of opportunity is pushing venture capital firms and healthcare investors to establish specialized funds to aid start-ups working on the treatment of dementia, which is slated to push more new healthcare companies to invest in dementia treatment going forward.

• In March 2023, EQT Life Sciences, a renowned healthcare investor based in the Netherlands, announced that it had closed its LSP Dementia Fund at approximately US$ 282.56 million, which is nearly US$ 100 million more than its initial target value. The fund is dedicated to investing in new companies working on bringing novel solutions for people affected with dementia.
• ESP Diagnostics, a United Kingdom-based start-up is focusing on developing a new early detection test for dementia with Lewy bodies and Parkinson’s disease. The extracellular synucleinopathic protein test is estimated to hit the European markets by the end of 2023.

Start-ups can benefit by learning more about aspects such as local supply, pricing trends, product standards, safety regulations, and new developments that have been discussed extensively in this Lewy body dementia treatment industry study by skilled analysts at Fact.MR, a market research and competitive intelligence provider.

Country-wise Insights

Rapidly aging population of the world makes it an oyster for Lewy body dementia treatment companies and allows them to expand their business anywhere. Investing in the United States, China, Germany, Japan, and Italy could offer a much better return on investment over the coming years.

What Makes the United States a Key Market for Lewy Body Dementia Treatment?

“High Focus on Neurodegenerative Disease Research”

The United States is home to some of the most prominent research programs focusing on neurology and neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Supportive government initiatives, high private investments in neurology R&D, and the presence of key biotechnology and pharmaceutical companies are other factors that make the United States a moneymaking market for Lewy body dementia treatment providers.

Why is Japan a Leading Market for Lewy Body Dementia Treatment Providers?

“Prominent Presence of Senescent Demographic”

Japan’s rapidly aging population is neither a secret nor a surprise to anyone. The risk of dementia and other neurodegenerative diseases is much higher in a geriatric population as compared to a demographic that’s under the age of 50 and this is why Japan is a highly rewarding market for Lewy body dementia treatment companies going forward.

• As per an article published in The Japan Times in September 2022, people 75 years of age accounted for over 15% of the total population of the country for the first time in history. 29.1% of the population was also found to be over 65 years of age.

Efforts to improve elder care and the establishment of new dementia care centers in the country are projected to create new opportunities for established as well as incoming Lewy body dementia treatment providers through 2033.

• Shinobu Yamanaka, a Japanese woman diagnosed with early-onset Alzheimer’s opened up a dementia care facility called Day Service Happy in the Kochi prefecture of Japan.

The problem of dementia is a severe one in Japan and people like Shinobu Yamanaka taking the initiative to deal with it themselves and help others to show how important it is to have a proper dementia treatment to help these people in the best way possible.

Which European Countries Should Lewy Body Dementia Treatment Providers Target?

“Italy, Portugal, Germany, and Greece Prime European Markets”

European countries are home to some of the most rapidly expanding geriatric populations in the world and Italy tops this chart at present. Tackling the dementia problem in Italy is crucial to its economic growth in the future as the country lost a good chunk of its working population in the COVID-19 pandemic.

• As per a news article published in March 2023, people of 65 years or more age accounted for around 23% of the total population of Italy and this made it the country with the highest share of 65+ year-old people in the European Union.

Similarly, Greece is also facing severe economic issues owing to its increasing aging population and this could prove to be a golden opportunity for Lewy body dementia treatment providers looking to enter the European markets. Germany, Portugal, and Bulgaria are among other noteworthy spaces that companies could target to establish their stronghold in the European region going forward.

Category-wise Insights

This Fact.MR research survey analyzes the Lewy body dementia treatment market based on drug type, indication, distribution channel, and region. Cholinesterase inhibitors are estimated to lead the global revenue generation charge over the next ten years with most sales accounted for by hospital pharmacies.

Which Lewy Body Dementia Treatment Drug is Most Popular?

“Cholinesterase Inhibitors Account for Leading Market Share”

Minimal side effects associated with the use of cholinesterase inhibitor drugs make them the most widely used medication for the treatment of Lewy body dementia. After cholinesterase inhibitors, antipsychotic drugs are the second-most used medications to help people suffering from Lewy body dementia.

Competitive Landscape

Product innovation is of the essence for Lewy body dementia treatment companies and this is why they are projected to invest heavily in R&D efforts across the study period and beyond. Lewy body dementia treatment drug providers are also estimated to focus on new launches to improve their sales potential in the long run.

• In January 2023, Biogen Inc., a renowned American biotechnology organization, announced that its marketing authorization application (MAA) for lecanemab was accepted by the European Medicines Agency (EMA). Lecanemab was also approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease on 6th January 2023.

Key Segments of Lewy Body Dementia Treatment Industry Research

• By Drug Type:

  • Cholinesterase Inhibitors
  • Antipsychotic Drugs
  • Carbidopa-Levodopa
  • Antidepressants
  • Benzodiazepine
  • Modafinil

• By Indication:

  • Dementia with Lewy Bodies (DLB)
  • Alzheimer’s Disease
  • Parkinson’s Disease

• By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

• By Region:

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA